Please assess the completion status of the following clinical trial:

Trial Title: A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects are non-immunocompromised males or females 18 years of age or older.~2. Subjects have ≥3% total body surface area plaque psoriasis.~3. Subjects are candidates for phototherapy or systemic therapy.~4. Subject must be diagnosed at least 6 months prior to entering the study.~5. Females must be surgically sterile, postmenopausal for \>5 years, or using a highly effective form of birth control (\<1% failure rate), for at least 30 days prior to test article exposure, with a negative serum pregnancy test.~Exclusion Criteria:~1. Subject is pregnant, lactating, or is planning to become pregnant during the study.~2. Subject is younger than 18 years of age.~3. Subjects with uncontrolled mental illness or active suicidal ideations based on baseline mental health questionnaire of choice.~4. Subject is known, or suspected of being unable to comply with the study protocol, in the opinion of the investigator.~5. Subject is currently enrolled in an investigational drug or device study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tildrakizumab 100 mg (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).